Doxorubicin
Nov 15, 2016
Aurobindo’s net profit; LLS selects; Eli Lilly secures; DNA vaccine against Zika
Aurobindo Pharma Q2 net profit up 33.53% to Rs. 606 cr Aurobindo Pharma reported 33.53 per cent rise in consolidated net profit to Rs 605.64 crore for the quarter ending September mainly on account of robust formulation sales. The company had posted a net profit after tax, minority interest and share of profit of jo...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
